ANNOUNCED AS TEMPORARYNo
On 28 October 2008, he French authorities notified the European Commission the individual aid project by Oséo in favor of the "Biointelligence" program.
BioIntelligence aims to develop software programs related to the biomedical and cosmetic sector.
Dassault Systčmes is leading the project, in partnership with five pharmaceutical companies (Pierre Fabre, Sanofi-Aventis, Servier and Bayer CropScienc ), two SME's specialized in softwares ( SoBioS and Auréus Pharma)and three French public research laboratories ( INRIA, INSERM and Genopole. ).
The aid will amount 118 210 033 EUR including 58 328 796 EUR for industrial research and 59 881 237 EUR for experimental development.
The program will be implementedfrom 01.01.2009 until 31.12.2013.
The European Commission gave the following assessment:
The program is financed by the French government trough the State agency Oséo and is therefore considered as state aid. The measure is selective since is it only given to a limited number of companies. By contributing to their R&D expenses, the measure provides beneficiaries an advantage. Since these companies operate in sectors that are open to intra-community trade, the measure is likely to affect trade. The given state aid will distort competitionsince the companies benefit from a strengthened position in comparison with other foreign competitors. (par. 94 of the letter from the European Commission to France - Brussels, 13.05.2009 C(2009) 3552 final 'French')
The Commission, however,has accordingly decided not to raise objections against the notified measure, since it fulfills the conditions to be considered compatible with the EC Treaty.
A state measure in the GTA database is assessed solely in terms of the extent to which its implementation affects the extent of discrimination against foreign commercial interests. On this metric, the state aid proposed here is discriminatory.
⚑ Please report this page in case you detect an inaccuracy in its content.